MYOZYME Side Effects

7013400-0 | Chills, Dyspepsia, Glomerulonephritis Membranous, Nephrotic Syndrome, Rash
on Sep 22, 2010 Female patient from SWITZERLAND , weighting 92.59 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient experienced the following unwanted or unexpected effects: chills, dyspepsia, glomerulonephritis membranous, nephrotic syndrome, rash (What is rash?). Myozyme dosage: 20 Mg/kg, Q2w. During the same period patient was treated with PANTOPRAZOLE SODIUM (20 Mg, Unk) (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), CLEMASTINE FUMARATE (1 Mg, Unk) (View Clemastine Fumarate Review and Clemastine Fumarate Label ). Patient was hospitalized.

7006413-6 | Cardiac Disorder, Respiratory Distress, Respiratory Syncytial Virus Bronchiolitis
Patient was taking Myozyme (View Usage). Patient had the following side effects: cardiac disorder, respiratory distress, respiratory syncytial virus bronchiolitis on Aug 31, 2010 from UNITED KINGDOM Additional patient health information: Female patient , weighting 20.28 lb, was diagnosed with glycogen storage disease type ii and. Myozyme dosage: 20 Mg/kg, Q2w, Intravenous. During the same period patient was treated with RANITIDINE (View Ranitidine Review and Ranitidine Label ). Patient was hospitalized.

7006042-4 | Cardiac Failure Congestive, Cardiomyopathy, Respiratory Failure
Adverse event was reported on Sep 14, 2010 by a Male patient taking Myozyme (View Usage) (Dosage: Unk) was diagnosed with glycogen storage disease type ii and. Location: ISRAEL , weighting 11.02 lb, After Myozyme was administered, patient had the following side effects: cardiac failure congestive, cardiomyopathy (What is cardiomyopathy?), respiratory failure. During the same period patient was treated with RITUXIMAB (60 Mg, Once) (View Rituximab Review and Rituximab Label ), METHOTREXATE (Unk) (View Methotrexate Review and Methotrexate Label ), DISOTHIAZIDE (1 Mg/kg, Qd) (View Disothiazide Review and Disothiazide Label ), FUSID (Unk) (View Fusid Review and Fusid Label ). Patient was hospitalized.

6998463-0 | Weight Increased
on Sep 07, 2010 Male patient from FRANCE , weighting 218.3 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient experienced the following unwanted or unexpected effects: weight increased. Myozyme dosage: 20 Mg/kg, Q2w. Patient was hospitalized.


6973055-8 | Deafness
on Sep 02, 2010 Female patient from NETHERLANDS , child 4 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient had the following side effects: deafness. Myozyme dosage: .

6973054-6 | Deafness
Patient was taking Myozyme (View Usage). After Myozyme was administered, patient had the following side effects: deafness on Sep 02, 2010 from NETHERLANDS Additional patient health information: Female patient , child 4 years of age, was diagnosed with glycogen storage disease type ii and. Myozyme dosage: .

6972541-4 | Respiratory Distress
Adverse event was reported on Aug 31, 2010 by a Female patient taking Myozyme (View Usage) (Dosage: 20 Mg/kg, Q2w) was diagnosed with glycogen storage disease type ii and. Location: INDIA , weighting 6.39 lb, Patient experienced the following unwanted or unexpected effects: respiratory distress. Patient was hospitalized.

6972532-3 | Cardiomyopathy
on Sep 06, 2010 Male patient from ISRAEL , weighting 11.02 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient had the following side effects: cardiomyopathy (What is cardiomyopathy?). Myozyme dosage: . During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6970426-0 | Oxygen Saturation Decreased, Upper Respiratory Tract Infection
on Aug 31, 2010 Female patient from UNITED KINGDOM , weighting 17.42 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). After Myozyme was administered, patient had the following side effects: oxygen saturation decreased, upper respiratory tract infection. Myozyme dosage: 200 Mg, Q2w. Patient was hospitalized.

6968505-7 | Cardiac Arrest, Renal Failure, Respiratory Failure, Urinary Tract Infection
Patient was taking Myozyme (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac arrest (What is cardiac arrest?), renal failure, respiratory failure, urinary tract infection (What is urinary tract infection?) on Aug 25, 2010 from JAPAN Additional patient health information: Female patient , weighting 61.73 lb, was diagnosed with glycogen storage disease type ii, sedation and. Myozyme dosage: 20 Mg/kg, Qow. During the same period patient was treated with MORPHINE HYDROCHLORIDE (.5 Mg, Unk) (View Morphine Hydrochloride Review and Morphine Hydrochloride Label ).

6964696-2 | Blood Pressure Increased, Brain Compression, Brain Neoplasm, Cerebellar Infarction, Cerebral Haemorrhage, Convulsion, Feeling Hot, Infusion Site Swelling, Intracranial Aneurysm
Adverse event was reported on Aug 17, 2010 by a Male patient taking Myozyme (View Usage) (Dosage: 1000 Mg, Q2w, Intravenous) was diagnosed with glycogen storage disease type ii and. Location: JAPAN , 14 years of age, weighting 116.8 lb, Patient had the following side effects: blood pressure increased, brain compression, brain neoplasm, cerebellar infarction, cerebral haemorrhage, convulsion, feeling hot, infusion site swelling, intracranial aneurysm. During the same period patient was treated with PREDNISOLONE SODIUM SUCCINATE INJ (View Prednisolone Sodium Succinate Inj Review and Prednisolone Sodium Succinate Inj Label ), HYDROXYZINE HCL (View Hydroxyzine Hcl Review and Hydroxyzine Hcl Label ). Patient was hospitalized.

6964695-0 | Brain Compression, Brain Stem Syndrome, Cerebellar Infarction, Cerebral Haemorrhage, Convulsion, Feeling Hot, Infusion Site Swelling, Intracranial Aneurysm, Loss Of Consciousness
on Aug 17, 2010 Male patient from JAPAN , 14 years of age, weighting 116.8 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). After Myozyme was administered, patient had the following side effects: brain compression, brain stem syndrome, cerebellar infarction, cerebral haemorrhage, convulsion, feeling hot, infusion site swelling, intracranial aneurysm, loss of consciousness. Myozyme dosage: 1000 Mg, Q2w, Intravenous. During the same period patient was treated with PREDNISOLONE SODIUM SUCCINATE INJ (View Prednisolone Sodium Succinate Inj Review and Prednisolone Sodium Succinate Inj Label ), HYDROXYZINE HCL (View Hydroxyzine Hcl Review and Hydroxyzine Hcl Label ). Patient was hospitalized.

6962176-1 | Cyanosis
on Aug 20, 2010 Male patient from MEXICO , weighting 13.23 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient experienced the following unwanted or unexpected effects: cyanosis. Myozyme dosage: 20 Mg/kg, Unk.

6960357-4 | Cerebral Haemorrhage, Fall
Patient was taking Myozyme (View Usage). Patient had the following side effects: cerebral haemorrhage, fall (What is fall?) on Aug 25, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 55.12 lb, was diagnosed with glycogen storage disease type ii and. Myozyme dosage: 20 Mg/kg, 1x/w. During the same period patient was treated with ALBUTEROL (Unk Unk, Unk) (View Albuterol Review and Albuterol Label ). Patient was hospitalized.

6960091-0 | Skin Lesion, Vasculitis
Adverse event was reported on Aug 23, 2010 by a Male patient taking Myozyme (View Usage) (Dosage: 20 Mg/kg, Q2w) was diagnosed with glycogen storage disease type ii and. Location: BRAZIL , 45 years of age, After Myozyme was administered, patient had the following side effects: skin lesion, vasculitis (What is vasculitis?).

6957578-3 | Barotrauma, Chest Pain, Dyspnoea, Headache, Muscle Atrophy, Oropharyngeal Pain, Oxygen Saturation Decreased, Pneumomediastinum, Pneumothorax
on Aug 19, 2010 Female patient from JAPAN , 39 years of age, weighting 72.09 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient experienced the following unwanted or unexpected effects: barotrauma, chest pain (What is chest pain?), dyspnoea, headache (What is headache?), muscle atrophy, oropharyngeal pain, oxygen saturation decreased, pneumomediastinum, pneumothorax. Myozyme dosage: Unk Unk, Unk. Patient was hospitalized.

6944836-1 | Nosocomial Infection
on Aug 19, 2010 Male patient from GERMANY , child 3 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient had the following side effects: nosocomial infection. Myozyme dosage: 40 Mg/kg, 1x/w. Patient was hospitalized.

6930735-8 | Arrhythmia, Blood Pressure Increased, Catheter Site Pain, Costochondritis, Infection, Infusion Site Extravasation, Vascular Access Complication
Patient was taking Myozyme (View Usage). After Myozyme was administered, patient had the following side effects: arrhythmia (What is arrhythmia?), blood pressure increased, catheter site pain, costochondritis, infection (What is infection?), infusion site extravasation, vascular access complication on Aug 09, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 138.7 lb, was diagnosed with glycogen storage disease type ii, chest pain (What is chest pain?) and. Myozyme dosage: 1250 Mg, Q2w. During the same period patient was treated with FOCALIN (View Focalin Review and Focalin Label ), MICROGESTIN 1.5/30 (View Microgestin 1.5/30 Review and Microgestin 1.5/30 Label ), ADVAIR DISKUS 100/50 (View Advair Diskus 100/50 Review and Advair Diskus 100/50 Label ), NASONEX (View Nasonex Review and Nasonex Label ), IBUPROFEN (600 Mg, Unk) (View Ibuprofen Review and Ibuprofen Label ). Patient was hospitalized.

6928189-0 | Bronchospasm, Dysphagia, Gastrointestinal Motility Disorder, Gastrooesophageal Reflux Disease, Hypotonia, Lung Disorder, Pyrexia, Respiratory Disorder
Adverse event was reported on Aug 05, 2010 by a Female patient taking Myozyme (View Usage) (Dosage: Unk Unk, Unk) was diagnosed with glycogen storage disease type ii and. Location: BRAZIL , weighting 26.01 lb, Patient experienced the following unwanted or unexpected effects: bronchospasm, dysphagia, gastrointestinal motility disorder, gastrooesophageal reflux disease, hypotonia, lung disorder, pyrexia, respiratory disorder. Patient was hospitalized.

6910852-9 | Rash Maculo-papular, Respiratory Arrest, Respiratory Distress
on Jul 27, 2010 Male patient from TURKEY , weighting 11.02 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient had the following side effects: rash maculo-papular, respiratory arrest, respiratory distress. Myozyme dosage: 20 Mg/kg, Q2w. During the same period patient was treated with PROPRANOLOL HYDROCHLORIDE (10 Mg/kg, Bid) (View Propranolol Hydrochloride Review and Propranolol Hydrochloride Label ), CEFTRIAXONE (400 Mg/kg, Bid) (View Ceftriaxone Review and Ceftriaxone Label ). Patient was hospitalized.

6910849-9 | Diarrhoea, Feeding Disorder, Increased Upper Airway Secretion, Lobar Pneumonia, Otitis Media, Pyrexia, Respiratory Failure, Vomiting
on Jul 27, 2010 Female patient from UNITED STATES , weighting 30.42 lb, was diagnosed with glycogen storage disease type ii, bronchial disorder, respiratory tract inflammation, hypertension, blood iron decreased, hypersensitivity, constipation (What is constipation?) and was treated with Myozyme (View Usage). After Myozyme was administered, patient had the following side effects: diarrhoea, feeding disorder, increased upper airway secretion, lobar pneumonia, otitis media, pyrexia, respiratory failure, vomiting. Myozyme dosage: 350 Mg, Q2w. During the same period patient was treated with ALBUTEROL (2.5 Mg, Bid) (View Albuterol Review and Albuterol Label ), PULMICORT (0.25 Mg, Bid) (View Pulmicort Review and Pulmicort Label ), ATENOLOL (0.25 Mg, Bid) (View Atenolol Review and Atenolol Label ), FERROUS SULFATE (20 Mg, Bid) (View Ferrous Sulfate Review and Ferrous Sulfate Label ), CLARITIN (4 Mg, Qd) (View Claritin Review and Claritin Label ), MAXITROL (Unk Unk, Prn) (View Maxitrol Review and Maxitrol Label ), MULTIVIT (1 U, Qd) (View Multivit Review and Multivit Label ), MIRALAX (4.25 Mg, Qod) (View Miralax Review and Miralax Label ). Patient was hospitalized.

6910245-4 | Nephrolithiasis
Patient was taking Myozyme (View Usage). Patient experienced the following unwanted or unexpected effects: nephrolithiasis on Jul 26, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 280.0 lb, was diagnosed with glycogen storage disease type ii and. Myozyme dosage: 20 Mg/kg, Q2w. Patient was hospitalized.

6901102-8 | Chills, Dyspepsia, Glomerulonephritis Membranous, Nephrotic Syndrome, Rash
Adverse event was reported on Jul 21, 2010 by a Female patient taking Myozyme (View Usage) (Dosage: 20 Mg/kg, Q2w) was diagnosed with glycogen storage disease type ii and. Location: SWITZERLAND , weighting 92.59 lb, Patient had the following side effects: chills, dyspepsia, glomerulonephritis membranous, nephrotic syndrome, rash (What is rash?). During the same period patient was treated with PANTOZOL (20 Mg, Unk) (View Pantozol Review and Pantozol Label ), CLEMASTINE FUMARATE (1 Mg, Unk) (View Clemastine Fumarate Review and Clemastine Fumarate Label ). Patient was hospitalized.

6883983-X | Pneumonia, Respiratory Failure
on Jul 17, 2010 Female patient from JAPAN , weighting 55.12 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). After Myozyme was administered, patient had the following side effects: pneumonia (What is pneumonia?), respiratory failure. Myozyme dosage: Unk Unk, Unk.

6880774-0 |
on Jul 14, 2010 Male patient from TAIWAN, PROVINCE OF CHINA , weighting 152.1 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). . Myozyme dosage: 20 Mg/kg, Q2w.

6880542-X | Electrocardiogram Qt Prolonged, Respiratory Failure, Therapeutic Response Decreased
Patient was taking Myozyme (View Usage). Patient had the following side effects: electrocardiogram qt prolonged, respiratory failure, therapeutic response decreased on Jul 15, 2010 from FRANCE Additional patient health information: Male patient , weighting 26.46 lb, was diagnosed with glycogen storage disease type ii and. Myozyme dosage: 30 Mg/kg, Q2w. During the same period patient was treated with POLARAMINE (0.5 Other, Unk) (View Polaramine Review and Polaramine Label ), SOLU MEDROL (5 Mg, Unk) (View Solu-medrol Review and Solu-medrol Label ).

6874559-9 | Abdominal Pain, Asthenia, Developmental Delay, Diarrhoea, Disease Progression, Face Oedema, Irritability, Motor Dysfunction, Myopathy
Adverse event was reported on Jul 09, 2010 by a Female patient taking Myozyme (View Usage) (Dosage: 20 Mg/kg, Q2w, Intravenous) was diagnosed with glycogen storage disease type ii and. Location: ISRAEL , child 6 years of age, weighting 41.45 lb, After Myozyme was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), asthenia, developmental delay, diarrhoea, disease progression, face oedema, irritability, motor dysfunction, myopathy.

6856193-X | Pyrexia
on Jul 06, 2010 Male patient from UNITED STATES , weighting 14.70 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient experienced the following unwanted or unexpected effects: pyrexia. Myozyme dosage: 20 Mg/kg, Q2w. Patient was hospitalized.

6845525-4 | Bacterial Tracheitis, Bronchitis Viral, Collapse Of Lung, Disease Complication, Dysmyelination, Electrocardiogram St Segment Depression, Glycogen Storage Disease Type Ii, Hypercapnia, Immobile
on Jun 30, 2010 Female patient from UNITED STATES , weighting 26.01 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient had the following side effects: bacterial tracheitis, bronchitis viral, collapse of lung, disease complication, dysmyelination, electrocardiogram st segment depression, glycogen storage disease type ii, hypercapnia, immobile. Myozyme dosage: 20 Mg/kg, Q2w, Intravenous. Patient was hospitalized.

6837708-4 | Abdominal Pain, Asthenia, Blood Immunoglobulin G Increased, Developmental Delay, Diarrhoea, Disease Progression, Face Oedema, Infusion Related Reaction
Patient was taking Myozyme (View Usage). After Myozyme was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), asthenia, blood immunoglobulin g increased, developmental delay, diarrhoea, disease progression, face oedema, infusion related reaction on Jun 27, 2010 from ISRAEL Additional patient health information: Female patient , child 6 years of age, weighting 41.45 lb, was diagnosed with glycogen storage disease type ii and. Myozyme dosage: 20 Mg/kg, Q2w, Intravenous.

6836190-0 | Diarrhoea, Feeding Disorder, Increased Upper Airway Secretion, Lobar Pneumonia, Otitis Media, Pyrexia, Respiratory Failure, Vomiting
Adverse event was reported on Jul 01, 2010 by a Female patient taking Myozyme (View Usage) (Dosage: 350 Mg, Q2w) was diagnosed with glycogen storage disease type ii, bronchial disorder, respiratory tract inflammation, hypertension, blood iron decreased, hypersensitivity, constipation (What is constipation?) and. Location: UNITED STATES , weighting 30.42 lb, Patient experienced the following unwanted or unexpected effects: diarrhoea, feeding disorder, increased upper airway secretion, lobar pneumonia, otitis media, pyrexia, respiratory failure, vomiting. During the same period patient was treated with ALBUTEROL (2.5 Mg, Bid) (View Albuterol Review and Albuterol Label ), PULMICORT (0.25 Mg, Bid) (View Pulmicort Review and Pulmicort Label ), ATENOLOL (0.25 Mg, Bid) (View Atenolol Review and Atenolol Label ), FERROUS SULFATE (20 Mg, Bid) (View Ferrous Sulfate Review and Ferrous Sulfate Label ), CLARITIN (4 Mg, Qd) (View Claritin Review and Claritin Label ), MAXITROL (Unk Unk, Prn) (View Maxitrol Review and Maxitrol Label ), MULTIVIT (1 U, Qd) (View Multivit Review and Multivit Label ), MIRALAX (4.25 Mg, Qod) (View Miralax Review and Miralax Label ). Patient was hospitalized.

6832043-2 | Disease Progression
on Jul 02, 2010 Female patient from UNITED KINGDOM , weighting 66.14 lb, was diagnosed with glycogen storage disease type ii, poor quality sleep, constipation (What is constipation?) and was treated with Myozyme (View Usage). Patient had the following side effects: disease progression. Myozyme dosage: 40 Mg/kg, Q2w. During the same period patient was treated with MELATONIN (7.5 Mg, Unk) (View Melatonin Review and Melatonin Label ), HYOSCINE HBR HYT (150 Mcg, Unk) (View Hyoscine Hbr Hyt Review and Hyoscine Hbr Hyt Label ), NULYTELY (Unk Unk, Qd) (View Nulytely Review and Nulytely Label ), COLISTIN (4.0 Unk, Qd) (View Colistin Review and Colistin Label ), CARBOCISTEINE (500 Mg, Unk) (View Carbocisteine Review and Carbocisteine Label ), AUGMENTIN '125' (562 Mg, Unk) (View Augmentin '125' Review and Augmentin '125' Label ).

6829812-1 | Blood Glucose Increased, Bradycardia, Hypotension, Pallor, Syncope, Unresponsive To Stimuli
on Jun 23, 2010 Female patient from UNITED STATES , 58 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). After Myozyme was administered, patient had the following side effects: blood glucose increased, bradycardia, hypotension, pallor, syncope, unresponsive to stimuli. Myozyme dosage: 20 Mg/kg, Q2w, Intravenous. Patient was hospitalized.

6817630-X | Depression, Glomerulonephritis Membranous, Nephritic Syndrome
Patient was taking Myozyme (View Usage). Patient experienced the following unwanted or unexpected effects: depression (What is depression?), glomerulonephritis membranous, nephritic syndrome on Jun 24, 2010 from UNITED KINGDOM Additional patient health information: Female patient , weighting 132.3 lb, was diagnosed with glycogen storage disease type ii and. Myozyme dosage: 20 Mg/kg, Q2w. During the same period patient was treated with VITAMIN D (Unk Unk, Unk) (View Vitamin D Review and Vitamin D Label ), CALCIUM CARBONATE (Unk Unk, Unk) (View Calcium Carbonate Review and Calcium Carbonate Label ), QUETIAPINE (Unk Unk, Unk) (View Quetiapine Review and Quetiapine Label ), CITALOPRAM (Unk Unk, Unk) (View Citalopram Review and Citalopram Label ).

6815406-0 | Scoliosis
Adverse event was reported on Jun 24, 2010 by a Male patient taking Myozyme (View Usage) (Dosage: 20 Mg/kg, Qow) was diagnosed with glycogen storage disease type ii and. Location: UNITED STATES , weighting 71.65 lb, Patient had the following side effects: scoliosis. Patient was hospitalized.

6814533-1 | Bacterial Tracheitis, Bronchitis Viral, Collapse Of Lung, Demyelination, Disease Complication, Dysmyelination, Dysstasia, Electrocardiogram St Segment Depression, Fatigue
on Jun 16, 2010 Female patient from UNITED STATES , weighting 26.01 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). After Myozyme was administered, patient had the following side effects: bacterial tracheitis, bronchitis viral, collapse of lung, demyelination, disease complication, dysmyelination, dysstasia, electrocardiogram st segment depression, fatigue. Myozyme dosage: 20 Mg/kg, Q2w, Intravenous. Patient was hospitalized.

6810135-1 | Chills, Dyspepsia, Glomerulonephritis Membranous, Nephrotic Syndrome, Rash
on Jun 17, 2010 Female patient from SWITZERLAND , weighting 92.59 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient experienced the following unwanted or unexpected effects: chills, dyspepsia, glomerulonephritis membranous, nephrotic syndrome, rash (What is rash?). Myozyme dosage: 20 Mg/kg, Q2w. During the same period patient was treated with PANTOZOL (20 Mg, Unk) (View Pantozol Review and Pantozol Label ), CLEMASTINE FUMARATE (1 Mg, Unk) (View Clemastine Fumarate Review and Clemastine Fumarate Label ). Patient was hospitalized.

6780168-2 | Disease Progression, Glycogen Storage Disease Type Ii
Patient was taking Myozyme (View Usage). Patient had the following side effects: disease progression, glycogen storage disease type ii on Jun 08, 2010 from UNITED KINGDOM Additional patient health information: Female patient , weighting 66.14 lb, was diagnosed with glycogen storage disease type ii, poor quality sleep, constipation (What is constipation?) and. Myozyme dosage: 40 Mg/kg, Q2w. During the same period patient was treated with MELATONIN (7.5 Mg, Unk) (View Melatonin Review and Melatonin Label ), HYOSCINE HBR HYT (150 Mcg, Unk) (View Hyoscine Hbr Hyt Review and Hyoscine Hbr Hyt Label ), NULYTELY (Unk Unk, Qd) (View Nulytely Review and Nulytely Label ), COLISTIN (4.0 Unk, Qd) (View Colistin Review and Colistin Label ), CARBOCISTEINE (500 Mg, Unk) (View Carbocisteine Review and Carbocisteine Label ), AUGMENTIN '125' (562 Mg, Unk) (View Augmentin '125' Review and Augmentin '125' Label ).

6773611-6 | Blood Immunoglobulin G Increased, Cerebral Atrophy, Disease Complication, Dysmyelination, Dyspnoea, Glycogen Storage Disease Type Ii, Hypercapnia, Hypoxia
Adverse event was reported on Jun 03, 2010 by a Female patient taking Myozyme (View Usage) (Dosage: 20 Mg/kg, Q2w, Intravenous) was diagnosed with glycogen storage disease type ii and. Location: UNITED STATES , weighting 27.56 lb, After Myozyme was administered, patient had the following side effects: blood immunoglobulin g increased, cerebral atrophy, disease complication, dysmyelination, dyspnoea, glycogen storage disease type ii, hypercapnia, hypoxia. Patient was hospitalized.

6766308-X | Hypersensitivity, Oral Candidiasis, Pyrexia, Tachycardia
on May 31, 2010 Female patient from TAIWAN, PROVINCE OF CHINA , weighting 7.39 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient experienced the following unwanted or unexpected effects: hypersensitivity, oral candidiasis, pyrexia, tachycardia. Myozyme dosage: 100 Mg, Unk. Patient was hospitalized.

6763751-X | Bronchospasm, Dysphagia, Gastrointestinal Motility Disorder, Gastrooesophageal Reflux Disease, Hypotonia, Pyrexia, Respiratory Disorder
on May 27, 2010 Female patient from BRAZIL , weighting 26.01 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient had the following side effects: bronchospasm, dysphagia, gastrointestinal motility disorder, gastrooesophageal reflux disease, hypotonia, pyrexia, respiratory disorder. Myozyme dosage: Unk Unk, Unk. Patient was hospitalized.

6763694-1 | Depression, Glomerulonephritis Membranous, Nephritic Syndrome
Patient was taking Myozyme (View Usage). After Myozyme was administered, patient had the following side effects: depression (What is depression?), glomerulonephritis membranous, nephritic syndrome on May 31, 2010 from UNITED KINGDOM Additional patient health information: Female patient , weighting 132.3 lb, was diagnosed with glycogen storage disease type ii and. Myozyme dosage: 20 Mg/kg, Q2w. During the same period patient was treated with VITAMIN D (Unk Unk, Unk) (View Vitamin D Review and Vitamin D Label ), CALCIUM CARBONATE (Unk Unk, Unk) (View Calcium Carbonate Review and Calcium Carbonate Label ), QUETIAPINE (Unk Unk, Unk) (View Quetiapine Review and Quetiapine Label ), CITALOPRAM (Unk Unk, Unk) (View Citalopram Review and Citalopram Label ).

6760362-7 | Apnoea, Erythema, Rash Erythematous
Adverse event was reported on May 26, 2010 by a Female patient taking Myozyme (View Usage) (Dosage: 20 Mg/kg, Qow) was diagnosed with glycogen storage disease type ii and. Location: UNITED STATES , weighting 21.61 lb, Patient experienced the following unwanted or unexpected effects: apnoea, erythema, rash erythematous. During the same period patient was treated with TYLENOL (View Tylenol Review and Tylenol Label ), BENADRYL (View Benadryl Review and Benadryl Label ).

6758146-9 | Chills, Dyspepsia, Glomerulonephritis Membranous, Nephrotic Syndrome, Rash
on May 25, 2010 Female patient from SWITZERLAND , weighting 92.59 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient had the following side effects: chills, dyspepsia, glomerulonephritis membranous, nephrotic syndrome, rash (What is rash?). Myozyme dosage: 20 Mg/kg, Q2w. During the same period patient was treated with PANTOZOL (20 Mg, Unk) (View Pantozol Review and Pantozol Label ), CLEMASTINE FUMARATE (1 Mg, Unk) (View Clemastine Fumarate Review and Clemastine Fumarate Label ). Patient was hospitalized.

6756039-4 | Pseudomonas Infection, Pyrexia, Respiratory Distress
on May 24, 2010 Male patient from UNITED STATES , weighting 16.98 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). After Myozyme was administered, patient had the following side effects: pseudomonas infection, pyrexia, respiratory distress. Myozyme dosage: 20 Mg/kg, Q2w. Patient was hospitalized.

6747060-0 | Apnoea, Erythema, Rash Erythematous
Patient was taking Myozyme (View Usage). Patient experienced the following unwanted or unexpected effects: apnoea, erythema, rash erythematous on May 21, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 21.61 lb, was diagnosed with glycogen storage disease type ii and. Myozyme dosage: 20 Mg/kg, Qow. During the same period patient was treated with TYLENOL (CAPLET) (View Tylenol (caplet) Review and Tylenol (caplet) Label ), BENADRYL (View Benadryl Review and Benadryl Label ).

6743974-6 | Cardiac Disorder
Adverse event was reported on May 14, 2010 by a Male patient taking Myozyme (View Usage) (Dosage: Unk Unk, Unk) was diagnosed with glycogen storage disease type ii and. Location: UNITED STATES , child 4 years of age, Patient had the following side effects: cardiac disorder.

6743525-6 | Acute Myeloid Leukaemia, Infusion Related Reaction, Weight Increased
on May 16, 2010 Male patient from CHINA , 31 years of age, weighting 149.9 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). After Myozyme was administered, patient had the following side effects: acute myeloid leukaemia, infusion related reaction, weight increased. Myozyme dosage: 20 Mg/kg, Q2w, Intravenous. During the same period patient was treated with TRETINOIN (View Tretinoin Review and Tretinoin Label ).

6737920-9 | Diarrhoea, Pseudomonas Infection, Pyrexia, Respiratory Distress, Vomiting
on May 13, 2010 Male patient from UNITED STATES , weighting 16.98 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, pseudomonas infection, pyrexia, respiratory distress, vomiting. Myozyme dosage: 20 Mg/kg, Q2w. Patient was hospitalized.

6735637-8 | Glomerulonephritis Membranous, Nephrotic Syndrome, Rash
Patient was taking Myozyme (View Usage). Patient had the following side effects: glomerulonephritis membranous, nephrotic syndrome, rash (What is rash?) on May 17, 2010 from SWITZERLAND Additional patient health information: Female patient , weighting 92.59 lb, was diagnosed with glycogen storage disease type ii and. Myozyme dosage: 20 Mg/kg, Q2w. Patient was hospitalized.